Trails Edge Capital Partners
Latest statistics and disclosures from Trails Edge Capital Partners's latest quarterly 13F-HR filing:
- Central Index Key (CIK): 0002077247
Tip: Access up to 7 years of quarterly data
Positions held by Trails Edge Capital Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Trails Edge Capital Partners
Trails Edge Capital Partners holds 26 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Vaxcyte (PCVX) | 8.8 | $39M | 663k | 58.11 |
|
|
| Xenon Pharmaceuticals (XENE) | 8.5 | $37M | 640k | 58.15 |
|
|
| Definium Therapeutics Com Shs (DFTX) | 7.5 | $33M | 1.7M | 18.90 |
|
|
| Lb Pharmaceuticals Com Shs (LBRX) | 7.5 | $33M | 1.3M | 24.66 |
|
|
| Mirum Pharmaceuticals (MIRM) | 7.1 | $31M | 333k | 92.38 |
|
|
| Nurix Therapeutics (NRIX) | 6.2 | $27M | 1.7M | 15.50 |
|
|
| Revolution Medicines (RVMD) | 5.5 | $24M | 245k | 97.25 |
|
|
| Arcus Biosciences Incorporated (RCUS) | 5.2 | $23M | 1.0M | 21.60 |
|
|
| Immunocore Hldgs Ads (IMCR) | 4.7 | $21M | 683k | 30.15 |
|
|
| Cytokinetics Com New (CYTK) | 4.5 | $20M | 300k | 65.91 |
|
|
| Syndax Pharmaceuticals (SNDX) | 3.8 | $16M | 702k | 23.36 |
|
|
| Neurogene (NGNE) | 3.6 | $16M | 783k | 20.16 |
|
|
| Inventiva Sa Ads (IVA) | 3.4 | $15M | 2.7M | 5.55 |
|
|
| Inhibikase Therapeutics Com New (IKT) | 3.1 | $14M | 8.1M | 1.68 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 2.8 | $12M | 1.3M | 9.31 |
|
|
| X4 Pharmaceuticals Com New (XFOR) | 2.4 | $11M | 2.6M | 4.13 |
|
|
| Immunovant (IMVT) | 2.4 | $10M | 414k | 24.84 |
|
|
| Design Therapeutics (DSGN) | 2.1 | $9.1M | 852k | 10.64 |
|
|
| Camp4 Therapeutics Corp (CAMP) | 2.0 | $8.6M | 1.9M | 4.41 |
|
|
| Minerva Neurosciences Com New (NERV) | 2.0 | $8.5M | 1.4M | 6.03 |
|
|
| Promis Neurosciences Com Shs (PMN) | 1.6 | $7.1M | 557k | 12.70 |
|
|
| Sol-gel Technologies Shs New (SLGL) | 1.6 | $6.8M | 86k | 79.22 |
|
|
| Century Therapeutics (IPSC) | 1.3 | $5.5M | 2.4M | 2.26 |
|
|
| Vtv Therapeutics Cl A New (VTVT) | 1.3 | $5.5M | 140k | 39.66 |
|
|
| Sensei Biotherapeutics Com New (SNSE) | 0.9 | $3.9M | 125k | 31.52 |
|
|
| Ocuphire Pharma (IRD) | 0.5 | $2.3M | 500k | 4.55 |
|
Past Filings by Trails Edge Capital Partners
SEC 13F filings are viewable for Trails Edge Capital Partners going back to 2026
- Trails Edge Capital Partners 2026 Q1 filed May 15, 2026